Breaking
Intel, AMD Extend Losses as Chip Selloff Hits Seventh Session
Nasdaq Futures Plunge 380 Points as AI Selloff Deepens; PPI, Retail Sales in Focus
Intel, AMD Extend Losses as Chip Selloff Hits Seventh Session
Nasdaq Futures Plunge 380 Points as AI Selloff Deepens; PPI, Retail Sales in Focus
Priya Sharma
Analyst

Priya Sharma

Equity & ETF Correspondent

Priya covers US and international equities, ETFs, and index funds. Her analysis focuses on long-term portfolio construction and dividend investing strategies.

Priya Sharma's Articles (966)
KOSPI reclaims 7,000 as AI chip demand offsets oil spike
Stocks
KOSPI reclaims 7,000 as AI chip demand offsets oil spike
SoftBank shares surge 5% as AI gains trump yen strength
Stocks
SoftBank shares surge 5% as AI gains trump yen strength
AMD shares climb 6% as AI chip market forecast hits $3T by 2030
Stocks
AMD shares climb 6% as AI chip market forecast hits $3T by 2030
CoreWeave stock jumps 16% on OpenAI's Astra model and $104B backlog
Stocks
CoreWeave stock jumps 16% on OpenAI's Astra model and $104B backlog
Marvell stock slides 31% from peak as valuation concerns mount
Stocks
Marvell stock slides 31% from peak as valuation concerns mount
Astera Labs rebounds: growth outlook supports further upside
Stocks
Astera Labs rebounds: growth outlook supports further upside
Nvidia slips 1.5% as AI peers rally; analysts see 30% upside
Stocks
Nvidia slips 1.5% as AI peers rally; analysts see 30% upside
ALLW ETF: Ray Dalio's All Weather Strategy Underperforms S&P 500
ETFs
ALLW ETF: Ray Dalio's All Weather Strategy Underperforms S&P 500
Micron stock builds momentum ahead of earnings, analysts see 27% upside
Stocks
Micron stock builds momentum ahead of earnings, analysts see 27% upside
Bitcoin Japan CEO: AI, SpaceX, and rare earths drive new strategy
Stocks
Bitcoin Japan CEO: AI, SpaceX, and rare earths drive new strategy
Micron, SanDisk rise premarket as memory rally masks consumer demand risk
Stocks
Micron, SanDisk rise premarket as memory rally masks consumer demand risk
Novartis drops 10% as second late-stage trial fails; PT cut
Stocks
Novartis drops 10% as second late-stage trial fails; PT cut